A review post-vaccination SARS-CoV-2 serological test: Method and antibody titer responseArticle Published on 2022-12-012022-11-15 Journal: Analytical biochemistry [Category] COVID19(2023년), SARS, 진단, [키워드] Antibody titer chemiluminescent immunoassay CLIA CMIA Convalescent plasma therapy Coronavirus disease 2019 COVID-19 Efficacy effort ELISA human donor identify immune response Immune titer immunoassay Lateral LFIA pandemic plaque PRNT reactive SARS-CoV-2 serological serological test Serologist Serologist method serology test Test Vaccine Vaccines [DOI] 10.1016/j.ab.2022.114902 PMC 바로가기
Central Retinal Vein Occlusion After Discontinuation of Rivaroxaban Therapy in a Young Patient with COVID-19 Pulmonary Embolism: A Case ReportArticle Published on 2022-11-012022-11-15 Journal: The American journal of case reports [Category] 진단, [키워드] anticoagulation Combination common contributing to Convalescent plasma therapy Course COVID-19 decrease Dexamethasone diagnosed discharge edema Factor healthy Hospitalized hypercoagulability initiated intravitreal injection knowledge occurred Oxygen therapy Patient Prophylactic pulmonary rebound Remdesivir report retinal vein retinal vein occlusion rivaroxaban Severe COVID-19 pneumonia significantly subsegmental the patient therapeutic therapy treated Treatment visual acuity was performed were excluded with COVID-19 [DOI] 10.12659/AJCR.937739 PMC 바로가기
Coronavirus disease 2019 subphenotypes and differential treatment response to convalescent plasma in critically ill adults: secondary analyses of a randomized clinical trialArticle Published on 2022-11-012022-11-15 Journal: Intensive care medicine [Category] Fulltext, MERS, 바이오마커, [키워드] ABO-compatible convalescent plasma Adaptive platform trial Adults Analysis assigned Biomarker Biomarkers chemokines community-acquired pneumonia convalescent plasma Convalescent plasma therapy coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 patient Critically ill critically ill patients Cytokines difference effector immune responses elevated endothelial explain heterogeneous homogeneous Hypothesis immunologically immunotherapies Inflammation IQR median multifactorial organ support outcome outcomes patients Population precision medicine Prevalence Randomized randomized clinical trial RCT RCTs REMAP-CAP reported secondary analysis Subphenotypes. tested therapy treatment effect Treatment response usual care with COVID-19 [DOI] 10.1007/s00134-022-06869-w PMC 바로가기
Blood Endothelial-Cell Extracellular Vesicles as Potential Biomarkers for the Selection of Plasma in COVID-19 Convalescent Plasma TherapyArticle Published on 2022-10-042022-11-15 Journal: Cells [Category] 바이오마커, [키워드] Activation age anti-SARS-CoV-2 antibody Biomarkers Blood blood endothelium cardiovascular disease caused CCP CCP therapy Characteristics characterized clinical symptom Concentration consequence convalescent plasma Convalescent plasma therapy coronavirus disease COVID-19 death Donor downregulation Endothelial cell Endothelial dysfunction Endothelium evidenced excessive inflammation expected extracellular vesicle Extracellular vesicles extracellular vesicles. hospital ICAM1 identify individual infected individual inflammatory storm massive secretion mechanism mild symptoms mitochondrial dysfunction multi-organ failure onset of symptom overexpression parameter Peripheral blood plasma Potential pro-inflammatory pro-inflammatory cytokine progression promoted reflected selected Selection severity subset Symptoms the disease therapy vaccination Vascular endothelium vascular inflammation vessel was increased [DOI] 10.3390/cells11193122 PMC 바로가기
Outpatient convalescent plasma therapy for high-risk patients with early COVID-19. A randomized placebo-controlled trialResearch article Published on 2022-08-012022-10-05 Journal: Clinical microbiology and infection : the official [Category] SARS, 임상, [키워드] antibodies benefit clinical conducted convalescent plasma Convalescent plasma therapy Course COVID-19 death determine died disease severity double blind duration of symptoms Effectiveness Endpoint enrolment Follow-up hazard ratio high-risk patient highest Hospital admission Hospitalized ICU admission IMPROVE in viral median age multicentre objective Odds ratio Older Outpatient outpatients Patient PCR primary endpoint randomization randomized placebo-controlled trial randomized trial recruitment Result risk factor RNA secondary severe COVID-19 Symptom symptom duration symptom onset symptomatic Symptoms the disease therapy for COVID-19 vaccination Viral RNA [DOI] 10.1016/j.cmi.2022.08.005 [Article Type] Research article
Drugs and convalescent plasma therapy for COVID-19: a survey of the interventional clinical studies in Italy after 1 year of pandemicCOVID-19에 대한 약물 및 회복기 혈장 요법: 대유행 1년 후 이탈리아의 중재적 임상 연구 조사Article Published on 2022-06-222022-09-11 Journal: Trials [Category] COVID19(2023년), SARS, 신약개발, 임상, [키워드] 2019 novel coronavirus adopted AIFA Analysis carried Characteristics clinical Clinical research clinical study clinical trial clinical trials convalescent plasma Convalescent plasma therapy coronavirus disease COVID-19 COVID-19 disease Critical disease drug drugs early phase effort Evidence experimental intervention feature Follow-up Health include Intervention investigated investigator investigators Italian Italy landscape majority Medicine methodological Novel coronavirus novel coronavirus disease pandemic parallel group performed platform prevention of COVID-19 Prophylactic Randomized recommendation Registered Replication replications Research Study design therapeutic Therapeutic approach Therapeutic class. therapeutic strategy Treatment Trial trials website were blinded [DOI] 10.1186/s13063-022-06474-8 PMC 바로가기 [Article Type] Article
Antibodies from convalescent plasma promote SARS-CoV-2 clearance in individuals with and without endogenous antibody response회복기 혈장의 항체는 내인성 항체 반응이 있거나 없는 개인에서 SARS-CoV-2 제거를 촉진합니다Clinical Trial Published on 2022-06-152022-09-11 Journal: The Journal of Clinical Investigation [Category] COVID19(2023년), MERS, SARS, 임상, 진단, 치료기술, [키워드] 95% CI absence Adaptive immunity adjusted hazard ratio adverse events affected antibody Antibody Response clearance Clinical research Comorbidity Comprehensive conducted convalescent plasma Convalescent plasma therapy Corona COVID-19 Critical demonstrated disease status Efficacy evidenced faster hazard ratio hospitalized COVID-19 patient human infection human infections Immunotherapy individual Innovation Intervention IQR Kaplan-Meier analysis laboratory parameter median interval Mortality neutralization Neutralizing neutralizing antibody onset of symptom parameter Phase I plasma plasma therapy pool principle priority Program promote recipient recipients Red respond Safe SARS-CoV-2 SARS-CoV-2 antibodies SARS-CoV-2 clearance SARS-CoV-2 vaccines serological significantly survival therapeutic Therapeutics therapy transfusion-related adverse event transfusion-related adverse events Trial university University of Zurich Viral viral clearance Viral load Viremia Virological virus clearance [DOI] 10.1172/JCI158190 PMC 바로가기 [Article Type] Clinical Trial
Short Communication: Prolonged COVID-19 Infection in a Patient with Newly Diagnosed HIV/AIDSCase Reports Published on 2022-05-012023-07-08 Journal: AIDS research and human retroviruses [Category] COVID19(2023년), [키워드] AIDS Convalescent plasma therapy COVID-19 HIV [DOI] 10.1089/AID.2021.0145 [Article Type] Case Reports
Convalescent plasma may not be an effective treatment for severe and critically ill covid-19 patients: A Systematic Review & Meta-Analysis of Randomized Controlled Trials회복기 혈장은 중증 및 중환자 코로나19 환자에게 효과적인 치료법이 아닐 수 있습니다: 무작위 대조 시험의 체계적인 검토 및 메타 분석Review Published on 2022-05-012022-09-11 Journal: Heart & lung : the journal of critical care [Category] 임상, 치료법, [키워드] 95% CI Clinical improvement conducted Controlled controlled trials convalescent plasma Convalescent plasma therapy convalescent plasma treatment Corona corona virus disease 2019 COVID-19 COVID-19 patient COVID-19 patients Critically ill database effective evaluate Meta-analysis moderate mortality risk no significant difference Patient plasma Primary outcome Primary outcomes Randomized controlled studies randomized controlled study Randomized controlled trial reduce review severe and critically ill COVID-19 patients systematic review Treatment Virus Disease [DOI] 10.1016/j.hrtlng.2022.01.019 PMC 바로가기 [Article Type] Review
Effect of convalescent plasma therapy on mortality in moderate-to-severely Ill COVID-19 patientsResearch article Published on 2022-05-012022-10-05 Journal: Transfusion and apheresis science : official journ [Category] COVID19(2023년), SARS, 치료제, [키워드] administration age analyzed association Blood Group CCP Comorbidities conducted convalescent plasma Convalescent plasma therapy correlated COVID-19 COVID-19 patient cut off value discharged disease disease severity Donor dosage Effect Effectiveness hemoglobin hospital Hospitalization Ill management moderate Mortality multicenter outcome pandemic parameter passive immunization Patient plasma plasma antibody protocol renal Research Result Retrospective study SARS CoV-2 Severe COVID-19 Infection severe disease significantly significantly higher single center survival therapy Treatment were recorded [DOI] 10.1016/j.transci.2022.103455 [Article Type] Research article